ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Journal and News Scan

Source: US Food and Drug Administration
Author(s): US Food and Drug Administration

The US FDA approved the Xvivo device for maintaining or resuscitating donor lungs prior to transplant. Interesting very high survival is reported in the control group at one year.

Source: The Annals of Thoracic Surgery
Author(s): Vinod H. Thourani, Sean M. O'Brien, John J. Kelly, David J. Cohen, Eric D. Peterson, Michael J. Mack, David M. Shahian, Frederick L. Grover, John D. Carroll, J. Matthew Brennan, Jessica Forcillo, Suzanne V. Arnold, Sreekanth Vemulapalli, Susan Fitzgerald, David R. Holmes, Joseph E. Bavaria, Fred H. Edwards

Thourani and colleagues used data from The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry to develop a risk model for in-hospital stroke after transcatheter aortic valve replacement (TAVR), a serious complication. Of the 97,600 TAVR procedures performed between 2014 and 2017 that were included in the analysis, 1,839 patients experienced in-hospital stroke. The authors limited covariate selection to patient demographics and baseline characteristics—with the one exception being access strategy—to increase the usefulness of the model prior to a procedure. Predictors for increased stroke risk included alternative access, prior stroke, procedural acuity, smoking, porcelain aorta, peripheral artery disease, and advanced age.

Additionally, the authors report that patients at 10 of the 521 participating sites were found to have significantly higher odds ratios for stroke than the other sites. They note that the model thus serves as a resource for quality improvement as well as for clinical decision making and patient counseling.

Source: The New England Journal of Medicine
Author(s): Catherine M. Otto

The overarching, free to read under terms, of the TAVR mini-compendium of this week: the most complex question remains "what is a reasonable expectation of a stakeholder on outcomes of aortic stenosis?"

Source: Annals of Cardiothoracic Surgery
Author(s): Carmelina C. Zirafa, Gaetano Romano, Teresa Hung Key, Federico Davini, Franca Melfi

Melfi and colleagues present a keynote lecture outlining the evolution of robotic thoracic surgery. The robotic technique in thoracic surgery has progressively become widespread, particularly for the treatment of mediastinal and pulmonary lesions. The authors discuss the development of technology in the robotic system that has been associated with the improvement of intraoperative and postoperative results.

Source: European Journal of Cardio-Thoracic Surgery
Author(s): Yoshiyuki Yamashita, Yasuhisa Oishi, Yuma Motomatsu, Kazuto Hirayama, Takeaki Harada, Tomoki Ushijima, Satoshi Fujita, Satoshi Kimura, Hiromichi Sonoda, Hideki Tatewaki, Yoshihisa Tanoue, Genya Sunagawa, Takuya Nishikawa, Keita Saku, Akira Shiose

Aortic endografting leads to aortic stiffening. In this experimental animal study, Yamashita and colleagues evaluated the effect that thoracic endografting had on cardiac afterload, function, and remodeling. The authors report increased aortic input impedance and left ventricular mass after three months, although the effect of experimental descending aorta endografting on left ventricular contractility and efficiency was minimal.

Source: The Journal of Thoracic and Cardiovascular Surgery
Author(s): Asha Singh, Xiaojie Huang, Lu Dai, Daniel Wyler, Andrej Alfirevic, Eugene H. Blackstone, Gosta B. Pettersson, Andra E. Duncan

The authors prospectively analyzed right ventricular (RV) function in 109 patients undergoing a broad range of cardiac surgeries. RV function was assessed at several time points by evaluating TAPSE and 2D longitudinal RV strain to evaluate long axis RV function, and fractional area exchange to evaluate global RV function. After CPB and after chest closure, reduced RV function was demonstrated across all cardiac procedures. Thus, there is a significant failure to protect the RV during surgery.

If one accepts these findings, what modes of myocardial protection should be assessed or re-assessed to protect the RV? Why or why not?

Source: The New England Journal of Medicine
Author(s): Ann E. Woolley, Steve K. Singh, Hilary J. Goldberg, Hari R. Mallidi, Michael M. Givertz, Mandeep R. Mehra, Antonio Coppolino, Amanda E. Kusztos, Megan E. Johnson, Kaiwen Chen, Esther A. Haddad, John Fanikos, David P. Harrington, Phillip C. Camp, Lindsey R. Baden, for the DONATE HCV Trial Team

The authors of this single-center open-label pilot trial evaluated the intermediate-term outcomes of patients undergoing either heart (n=8) or lung (n=36) transplantation from donors that had evidence of active hepatitis C virus (HCV) infection. All patients underwent treatment of HCV antiviral treatment for 4 weeks after transplantation. The primary outcome measured was a composite of a sustained virologic response at 12 weeks after completion of antiviral therapy for HCV infection and graft survival 6 months after transplantation. Of the initial 35 patients who had completed 6 months of follow-up, all patients met the primary outcome. Thus, at intermediate term follow-up, HCV infection was prevented in 100% of patients.

Source: The Annals of Thoracic Surgery
Author(s): Roberta E. Redfern, Kevin Fleming, Rebekah L. March, Nathan Bobulski, Michael Kuehne, John T. Chen, Michael Moront

This single-center study retrospectively analyzed the impact of the implementation of thromboelastography (TEG) on all cardiac procedures performed during 2-year intervals prior to and after TEG implementation. A total of 367 and 310 patients were included in the analysis for the pre-TEG and post-TEG eras, respectively. The authors found that the implementation of TEG was associated with a significant reduction in blood product usage, reoperation, postoperative LOS, and 6-month mortality.

Source: The Annals of Thoracic Surgery
Author(s): Tyler Wallen, Andreas Habertheuer, Joseph E. Bavaria, G.Chad Hughes, Vinay Badhwar, Jeffrey P. Jacobs, Babatunde Yerokun, Dylan Thibault, Karianna Milewski, Nimesh Desai, Wilson Szeto, Lars Svensson, Prashanth Vallabhajosyula

The authors analyzed the STS database for elective aortic root replacement (with several important exclusions) to derive risk factors for mortality and morbidity. A total of 8,807 patients met inclusion criteria. Significant predictors for mortality that were discovered include atrial fibrillation, body surface area, chronic obstructive pulmonary disease, NYHA IV, diabetes, concomitant coronary artery bypass grafting, concomitant mitral valve surgery, and Bentall operation.

Source: News from around the web.
Author(s): Claire Vernon

Patient Care and General Interest

Uruguay’s fight against tobacco and Phillip Morris was highlighted at the recent Annual Meeting of the American College of Cardiology, and one physician shares her thoughts.

The University of California Los Angeles has opened a new center, the Robert G. Kardashian Center for Esophageal Health, to focus on treatment, research, and education for esophageal disorders.

 

Drugs and Devices

Boston Scientific’s transcatheter Lotus Edge Aortic Valve System was cleared by the US Food and Drug Administration. The company launched the system recently in Europe and will launch it in the US soon.

Goggles that facilitated a mixed-reality view of 3D echocardiography were used for a percutaneous mitral valve intervention in Poland.

 

Research, Trials, and Funding

Researchers from St. Louis, Missouri, USA, report on the impact of a 2017 change in US lung transplant policy that expanded the geographic boundaries for determining which patients get first priority for donor lungs.

Simulation training improves a team’s ability to manage operating room fires more than training that is exclusively didactic, say researchers from Illinois, USA.

Pages